Original language | English |
---|---|
Pages (from-to) | 317-324 |
Number of pages | 8 |
Journal | Pharmacoeconomics |
Volume | 38 |
Issue number | 4 |
Early online date | 9 Dec 2019 |
DOIs | |
Publication status | Published - Apr 2020 |
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Willem J. A. Witlox*, Antoinette D. I. van Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore, Sabine E. Grimm
*Corresponding author for this work
Research output: Contribution to journal › Review article › peer-review